MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Pulmonx Corporation Operating Income 2011-2026 | LUNG
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Pulmonx Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -57.7 M | -61.9 M | -58.6 M | -47.3 M | -32.3 M | -17.8 M | -15.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -15.1 M | -61.9 M | -41.5 M |
Quarterly Operating Income Pulmonx Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.4 M | -14.8 M | -14.6 M | - | -14.1 M | -15.6 M | -14.5 M | - | -15.2 M | -16.4 M | -16.4 M | - | -13.9 M | -14.4 M | -15.7 M | - | -9.76 M | -12.7 M | -12.5 M | - | -5.35 M | -11.5 M | -6.1 M | - | -3.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.61 M | -16.4 M | -12.7 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M |  USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 38.78 | -1.25 % | $ 5.78 K | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 8.15 | 4.22 % | $ 585 M |  Israel |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 9.69 | 3.09 % | $ 1.31 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.15 | 4.01 % | $ 155 M |  France |
 |
Electromed
ELMD
|
9.66 M | $ 24.26 | 1.17 % | $ 205 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 43.13 | -0.43 % | $ 1.34 B | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.51 | 0.05 % | $ 121 M | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 29.17 | -2.21 % | $ 1.34 B | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.31 | 4.42 % | $ 115 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.53 | 0.68 % | $ 54.5 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Medigus Ltd.
MDGS
|
-9.9 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.79 | -1.24 % | $ 43 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 183.14 | 0.27 % | $ 13.7 B | USA |
 |
Inari Medical
NARI
|
-28.1 M | - | - | $ 4.23 B | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 3.99 | 7.7 % | $ 845 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
8.05 B | $ 113.59 | 0.01 % | $ 198 B | USA |
 |
Nevro Corp.
NVRO
|
-126 M | - | - | $ 217 M | USA |
 |
InMode Ltd.
INMD
|
85.4 M | $ 13.58 | -0.18 % | $ 878 M | Israel |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 72.75 | -1.49 % | $ 108 B | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 105.22 | 0.89 % | $ 1.33 B | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.42 | -0.7 % | $ 22.9 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.31 | 16.67 % | $ 1.4 M | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 13.05 | 0.23 % | $ 1.96 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 85.73 | 0.55 % | $ 50.1 B | USA |